374 related articles for article (PubMed ID: 33934680)
1. Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects.
de Barros JWF; Villela E Silva P; da Silva GV; da Silva KP; Borges CDS; Mueller A; Valencise L; Pupo AS; Kempinas WG
Drug Chem Toxicol; 2022 Sep; 45(5):2233-2245. PubMed ID: 33934680
[TBL] [Abstract][Full Text] [Related]
2. Lower sperm quality and testicular and epididymal structural impairment in adult rats exposed to rosuvastatin during prepuberty.
Leite GAA; Sanabria M; Cavariani MM; Anselmo-Franci JA; Pinheiro PFF; Domeniconi RF; Kempinas WG
J Appl Toxicol; 2018 Jun; 38(6):914-929. PubMed ID: 29460396
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term effects on reproductive parameters of female Wistar rats after exposure to rosuvastatin starting in pre-puberty.
Barros JWF; Tonon KS; Borges CS; Silva PV; Lozano AFQ; Pacheco TL; Anselmo-Franci JA; Kempinas WG
Curr Res Toxicol; 2020 Jun; 1():149-160. PubMed ID: 34345844
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 Cells.
Salunkhe VA; Elvstam O; Eliasson L; Wendt A
PLoS One; 2016; 11(3):e0151592. PubMed ID: 26986474
[TBL] [Abstract][Full Text] [Related]
5. Ascorbic acid supplementation partially prevents the delayed reproductive development in juvenile male rats exposed to rosuvastatin since prepuberty.
Leite GAA; Figueiredo TM; Sanabria M; Dias AFMG; Silva PVE; Martins Junior ADC; Barbosa Junior F; Kempinas WG
Reprod Toxicol; 2017 Oct; 73():328-338. PubMed ID: 28729172
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS.
Seker FB; Kilic U; Caglayan B; Ethemoglu MS; Caglayan AB; Ekimci N; Demirci S; Dogan A; Oztezcan S; Sahin F; Yilmaz B; Kilic E
Neuroscience; 2015 Jan; 284():349-359. PubMed ID: 25453767
[TBL] [Abstract][Full Text] [Related]
7. Uterotrophic and in vitro screening for (anti)estrogenic activity of dipyrone.
Passoni MT; Palu G; Grechi N; da Silva Amaral BA; Gomes C; Rülker C; van Ravenzwaay B; Martino-Andrade AJ
Toxicol Lett; 2021 Nov; 352():1-8. PubMed ID: 34536523
[TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid co-administered with rosuvastatin reduces reproductive impairment in the male offspring from male rats exposed to the statin at pre-puberty.
Leite GAA; Figueiredo TM; Guerra MT; Borges CDS; Fernandes FH; Anselmo-Franci JA; Kempinas WG
Food Chem Toxicol; 2018 Aug; 118():416-429. PubMed ID: 29778496
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.
Okada Y; Yamaguchi K; Nakajima T; Nishikawa T; Jo M; Mitsumoto Y; Kimura H; Nishimura T; Tochiki N; Yasui K; Mitsuyoshi H; Minami M; Kagawa K; Okanoue T; Itoh Y
Liver Int; 2013 Feb; 33(2):301-11. PubMed ID: 23295058
[TBL] [Abstract][Full Text] [Related]
10. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
McTaggart F; Buckett L; Davidson R; Holdgate G; McCormick A; Schneck D; Smith G; Warwick M
Am J Cardiol; 2001 Mar; 87(5A):28B-32B. PubMed ID: 11256847
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.
Ikeda Y; Young LH; Lefer AM
J Cardiovasc Pharmacol; 2003 Apr; 41(4):649-56. PubMed ID: 12658068
[TBL] [Abstract][Full Text] [Related]
14. Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.
Ozturk N; Yaras N; Ozmen A; Ozdemir S
J Bioenerg Biomembr; 2013 Aug; 45(4):343-52. PubMed ID: 23640692
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs.
Satoh K; Takaguri A; Itagaki M; Kano S; Ichihara K
J Pharmacol Sci; 2008 Apr; 106(4):593-9. PubMed ID: 18403900
[TBL] [Abstract][Full Text] [Related]
16. Screening for in vivo (anti)estrogenic and (anti)androgenic activities of Tropaeolum majus L. and its effect on uterine contractility.
Lourenço EL; Muller JC; Boareto AC; Gomes C; Lourenço AC; Minatovicz B; Crestani S; Gasparotto A; Martino-Andrade AJ; Dalsenter PR
J Ethnopharmacol; 2012 May; 141(1):418-23. PubMed ID: 22433534
[TBL] [Abstract][Full Text] [Related]
17. Effects of isolated or combined exposure to sibutramine and rosuvastatin on reproductive parameters of adult male rats.
E Silva PV; Borges CDS; Rosa JL; Pacheco TL; Figueiredo TM; Leite GAA; Guerra MT; Anselmo-Franci JA; Klinefelter GR; Kempinas WG
J Appl Toxicol; 2020 Jul; 40(7):947-964. PubMed ID: 32072669
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Lopez LM
J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
[TBL] [Abstract][Full Text] [Related]
20. Evidence that 17alpha-estradiol is biologically active in the uterine tissue: antiuterotonic and antiuterotrophic action.
Perusquía M; Navarrete E
Reprod Biol Endocrinol; 2005 Jul; 3():30. PubMed ID: 16042770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
